187 related articles for article (PubMed ID: 22637734)
1. Identification of five novel modifier loci of Apc(Min) harbored in the BXH14 recombinant inbred strain.
Nnadi SC; Watson R; Innocent J; Gonye GE; Buchberg AM; Siracusa LD
Carcinogenesis; 2012 Aug; 33(8):1589-97. PubMed ID: 22637734
[TBL] [Abstract][Full Text] [Related]
2. Genetic analysis of intestinal polyp development in Collaborative Cross mice carrying the Apc (Min/+) mutation.
Dorman A; Baer D; Tomlinson I; Mott R; Iraqi FA
BMC Genet; 2016 Feb; 17():46. PubMed ID: 26896154
[TBL] [Abstract][Full Text] [Related]
3. Genetic mapping of novel modifiers for Apc
Dorman A; Binenbaum I; Abu-Toamih Atamni HJ; Chatziioannou A; Tomlinson I; Mott R; Iraqi FA
BMC Genomics; 2021 Jul; 22(1):566. PubMed ID: 34294033
[TBL] [Abstract][Full Text] [Related]
4. The CAST/Ei strain confers significant protection against Apc(Min) intestinal polyps, independent of the resistant modifier of Min 1 (Mom1) locus.
Koratkar R; Pequignot E; Hauck WW; Siracusa LD
Cancer Res; 2002 Oct; 62(19):5413-7. PubMed ID: 12359746
[TBL] [Abstract][Full Text] [Related]
5. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia.
Silverman KA; Koratkar R; Siracusa LD; Buchberg AM
Genome Res; 2002 Jan; 12(1):88-97. PubMed ID: 11779834
[TBL] [Abstract][Full Text] [Related]
6. Identification of Mom12 and Mom13, two novel modifier loci of Apc (Min) -mediated intestinal tumorigenesis.
Crist RC; Roth JJ; Lisanti MP; Siracusa LD; Buchberg AM
Cell Cycle; 2011 Apr; 10(7):1092-9. PubMed ID: 21386660
[TBL] [Abstract][Full Text] [Related]
7. Analysis of reciprocal congenic lines reveals the C3H/HeJ genome to be highly resistant to ApcMin intestinal tumorigenesis.
Koratkar R; Silverman KA; Pequignot E; Hauck WW; Buchberg AM; Siracusa LD
Genomics; 2004 Nov; 84(5):844-52. PubMed ID: 15475263
[TBL] [Abstract][Full Text] [Related]
8. ApcMin: a mouse model for intestinal and mammary tumorigenesis.
Moser AR; Luongo C; Gould KA; McNeley MK; Shoemaker AR; Dove WF
Eur J Cancer; 1995; 31A(7-8):1061-4. PubMed ID: 7576992
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel modifier loci of Apc Min affecting mammary tumor development.
Wang H; Teske D; Tess A; Kohlhepp R; Choi Y; Kendziorski C; Moser AR
Cancer Res; 2007 Dec; 67(23):11226-33. PubMed ID: 18056448
[TBL] [Abstract][Full Text] [Related]
10. Cysteinyl leukotriene 1 receptor influences intestinal polyp incidence in a gender-specific manner in the ApcMin/+ mouse model.
Savari S; Chandrashekar NK; Osman J; Douglas D; Bellamkonda K; Jönsson G; Juhas M; Greicius G; Pettersson S; Sjölander A
Carcinogenesis; 2016 May; 37(5):491-9. PubMed ID: 26979937
[TBL] [Abstract][Full Text] [Related]
11. Five quantitative trait loci control radiation-induced adenoma multiplicity in Mom1R Apc Min/+ mice.
Elahi E; Suraweera N; Volikos E; Haines J; Brown N; Davidson G; Churchman M; Ilyas M; Tomlinson I; Silver A
PLoS One; 2009; 4(2):e4388. PubMed ID: 19194513
[TBL] [Abstract][Full Text] [Related]
12. Reduction in alkaline sphingomyelinase in colorectal tumorigenesis is not related to the APC gene mutation.
Hertervig E; Nilsson A; Nilbert M; Duan RD
Int J Colorectal Dis; 2003 Jul; 18(4):309-13. PubMed ID: 12774245
[TBL] [Abstract][Full Text] [Related]
13. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice.
Yamada Y; Hata K; Hirose Y; Hara A; Sugie S; Kuno T; Yoshimi N; Tanaka T; Mori H
Cancer Res; 2002 Nov; 62(22):6367-70. PubMed ID: 12438216
[TBL] [Abstract][Full Text] [Related]
14. Genetic dissection of the Mom5 modifier locus and evaluation of Mom5 candidate genes.
Otterpohl KL; Gould KA
Mamm Genome; 2015 Jun; 26(5-6):235-47. PubMed ID: 25976411
[TBL] [Abstract][Full Text] [Related]
15. PWD/Ph-Encoded Genetic Variants Modulate the Cellular Wnt/β-Catenin Response to Suppress
Farrall AL; Lienhard M; Grimm C; Kuhl H; Sluka SHM; Caparros M; Forejt J; Timmermann B; Herwig R; Herrmann BG; Morkel M
Cancer Res; 2021 Jan; 81(1):38-49. PubMed ID: 33154092
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
[TBL] [Abstract][Full Text] [Related]
17. Evidence against dominant negative mechanisms of intestinal polyp formation by Apc gene mutations.
Oshima M; Oshima H; Kobayashi M; Tsutsumi M; Taketo MM
Cancer Res; 1995 Jul; 55(13):2719-22. PubMed ID: 7796392
[TBL] [Abstract][Full Text] [Related]
18. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
19. Apc mice: models, modifiers and mutants.
McCart AE; Vickaryous NK; Silver A
Pathol Res Pract; 2008; 204(7):479-90. PubMed ID: 18538487
[TBL] [Abstract][Full Text] [Related]
20. Resistant carbohydrates stimulate cell proliferation and crypt fission in wild-type mice and in the Apc(Min/+) mouse model of intestinal cancer, association with enhanced polyp development.
Mandir N; Englyst H; Goodlad RA
Br J Nutr; 2008 Oct; 100(4):711-21. PubMed ID: 18279550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
